
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
In this video interview we sit down with John Dobak, MD, and Laura Ferris, MD, PhD, to talk about DermTech, the TRUST study, and more.
In this exclusive interview with Dermatology Times®, John Dobak, MD, the president and CEO of
Laura Ferris, MD, PhD, a dermatologist and associate professor at the University of Pittsburgh Clinical and Translational Science Institute Director of Clinical Trials, UPMC Department of Dermatology, also talked about how to evaluate patient risk factors, patient education, and how Covid-19 has affected melanoma detection.